Vyome Holdings HIND
NASDAQ HIND
$2.06 -0.03 (-1.44%)
As of: Sep 9, 2026 · 3:59 PM EDT

Vyome Holdings (HIND) Non Operating Interest Expenses (2024 - 2026)

Vyome Holdings (HIND) posted Non Operating Interest Expenses of $3325.0 for Q2 2026, up 16.87% on a QoQ basis from $2845.0 in Q1 2026, and down 94.08% year-over-year from $56139.0 in Q2 2025.

Analysis

Vyome Holdings (HIND) Non Operating Interest Expenses (2024 - 2026) Analysis & Trends

Vyome Holdings has reported Non Operating Interest Expenses for 3 years, with the latest figure at $3325.0 in Q2 2026.

  • On a quarterly basis, Non Operating Interest Expenses fell 94.08% year-over-year to $3325.0 in Q2 2026; TTM through Jun 2026 was $41718.0, a 80.1% decrease from a year earlier, with the FY2025 full-year figure at $146641.0, down 28.82% from the prior year.
  • Non Operating Interest Expenses was $3325.0 for Q2 2026 at Vyome Holdings, up from $2845.0 in the prior quarter.
  • The five-year high for Non Operating Interest Expenses was $56139.0 in Q2 2025, with the low at $2845.0 in Q1 2026.
  • Average Non Operating Interest Expenses over 3 years is $31416.0, with a median of $35673.0 recorded in 2024.
  • The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses slumped 44.03% in 2025, then slumped 94.82% in 2026.
  • Over 3 years, Non Operating Interest Expenses stood at $52775.0 in 2024, then sank by 81.16% to $9944.0 in 2025, then slumped by 66.56% to $3325.0 in 2026.
  • The last three Non Operating Interest Expenses figures came in at $3325.0 (Q2 2026), $2845.0 (Q1 2026), and $9944.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Vyome Holdings 14.46 Mn 6.57 Mn 11,658.00 3,325.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3,325.00
Mar 31, 2026 2,845.00
Dec 31, 2025 9,944.00
Sep 30, 2025 25,604.00
Jun 30, 2025 56,139.00
Mar 31, 2025 54,954.00
Dec 31, 2024 52,775.00
Sep 30, 2024 45,742.00